Product Program year 2025 Source: CMS Open Payments

Biofinity Contact Lens

Device Devices

Open in the dashboard

General payments

$336,001

5,884 payments

Research payments

$1,386,470

43 payments

Through program year 2025, $336,001 in general payments and $1,386,470 in research payments were reported against Biofinity Contact Lens (Devices).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

12 rows
Year Kind Amount Payments
2025 General $76,776 754
2024 General $27,547 805
2024 Research $563,936 20
2023 General $34,970 815
2023 Research $264,079 9
2022 General $26,551 875
2022 Research $434,328 10
2021 General $41,896 658
2021 Research $71,811 3
2020 General $52,726 795
2019 General $75,534 1,182
2019 Research $52,315 1

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $336,001 5,884 payments
Top recipients General payments · program year 2025
  1. Lawrence Tavel General Practice · Indianapolis, IN $6,750 9% · 1 payment
  2. Michael Shaheen Optometrist · Canton, OH $5,782 8% · 12 payments
  3. Brian Gin Optometrist · Fremont, CA $3,000 4% · 1 payment
  4. Evan Kaplan Optometrist · Bronx, NY $3,000 4% · 1 payment
  5. Emma Loyfman Optometrist · Chicago, IL $3,000 4% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Optometrist $69,209 90% · 572 practitioners
  2. General Practice $6,750 9% · 1 practitioner
  3. Optometrist, Corneal and Contact Management Optometrist $353 <1% · 8 practitioners
  4. Ophthalmology $343 <1% · 8 practitioners
  5. Retina Specialist Ophthalmology $92 <1% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Ohio $11,522 15% · 34 recipients
  2. Indiana $9,389 12% · 10 recipients
  3. Texas $8,249 11% · 61 recipients
  4. Tennessee $5,614 7% · 9 recipients
  5. Virginia $5,163 7% · 61 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

5,884 general · 43 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record